REMS Class-Action Lawsuit Against Celgene Is First By Patients

Patients For Affordable Drugs Founder David Mitchell alleges Celgene's unlawful delay tactics like REMS obstruction kept generic versions of Thalomid and Revlimid off the market, forcing plaintiffs to pay higher costs.

GoldKeyInPuzzle_1200x675

While generic drugmakers have yet to be successful in stopping innovators using misusing Risk Evaluation and Mitigation Strategies (REMS) through the legal system, a patient advocate-led class action lawsuit is hoping for better fortunes in what looks to be the first non-manufacturer related complaint on the issue.

The lawsuit – filed June 14 in the US District Court for the District of New Jersey – is being...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet